211 related articles for article (PubMed ID: 36649695)
1. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract][Full Text] [Related]
2. GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.
Plage H; Samtleben H; Hofbauer S; Kornienko K; Weinberger S; Bruch PG; Elezkurtaj S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Klatte T; Schlomm T; Horst D; Zecha H
Hum Pathol; 2022 Dec; 130():10-17. PubMed ID: 36152841
[TBL] [Abstract][Full Text] [Related]
3. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
4. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M; McCue PA; Sarlomo-Rikala M; Rys J; Czapiewski P; Wazny K; Langfort R; Waloszczyk P; Biernat W; Lasota J; Wang Z
Am J Surg Pathol; 2014 Jan; 38(1):13-22. PubMed ID: 24145643
[TBL] [Abstract][Full Text] [Related]
5. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
6. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases.
Boto A; Harigopal M
Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697
[TBL] [Abstract][Full Text] [Related]
7. TRPS1 is a Highly Sensitive Marker for Breast Cancer: A Tissue Microarray Study Evaluating More Than 19,000 Tumors From 152 Different Tumor Entities.
Lennartz M; Löhr N; Höflmayer D; Dwertmann Rico S; von Bargen C; Kind S; Reiswich V; Viehweger F; Lutz F; Bertram V; Fraune C; Gorbokon N; Weidemann S; Blessin NC; Hube-Magg C; Menz A; Schlichter R; Krech T; Hinsch A; Burandt E; Sauter G; Simon R; Kluth M; Marx AH; Lebok P; Dum D; Minner S; Jacobsen F; Clauditz TS; Bernreuther C; Steurer S
Am J Surg Pathol; 2024 Apr; ():. PubMed ID: 38647255
[TBL] [Abstract][Full Text] [Related]
8. Desmoglein 3 (Dsg3) expression in cancer: A tissue microarray study on 15,869 tumors.
Viehweger F; Azem A; Gorbokon N; Uhlig R; Lennartz M; Dwertmann Rico S; Kind S; Reiswich V; Kluth M; Hube-Magg C; Bernreuther C; Büscheck F; Clauditz TS; Fraune C; Jacobsen F; Krech T; Lebok P; Steurer S; Burandt E; Minner S; Marx AH; Simon R; Sauter G; Menz A; Hinsch A
Pathol Res Pract; 2022 Dec; 240():154200. PubMed ID: 36375372
[TBL] [Abstract][Full Text] [Related]
9. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma.
So JS; Epstein JI
Mod Pathol; 2013 Oct; 26(10):1365-70. PubMed ID: 23599157
[TBL] [Abstract][Full Text] [Related]
10. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
Bruch PG; Plage H; Hofbauer S; Kornienko K; Weinberger S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Zecha H; Klatte T; Schlomm T; Horst D; Elezkurtaj S
Exp Mol Pathol; 2023 Jun; 131():104860. PubMed ID: 36997051
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
13. GATA3 immunohistochemical expression in salivary gland neoplasms.
Schwartz LE; Begum S; Westra WH; Bishop JA
Head Neck Pathol; 2013 Dec; 7(4):311-5. PubMed ID: 23604756
[TBL] [Abstract][Full Text] [Related]
14. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
15. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
16. Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
Kaczmarek K; Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Schallenberg S; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Zecha H
Int Urol Nephrol; 2024 Feb; 56(2):499-508. PubMed ID: 37777995
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers.
Rao Q; Williamson SR; Lopez-Beltran A; Montironi R; Huang W; Eble JN; Grignon DJ; Koch MO; Idrees MT; Emerson RE; Zhou XJ; Zhang S; Baldridge LA; Cheng L
Mod Pathol; 2013 May; 26(5):725-32. PubMed ID: 23348900
[TBL] [Abstract][Full Text] [Related]
18. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS
Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408
[TBL] [Abstract][Full Text] [Related]
20. TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
Bachert SE; Di J; Zhang S; Short HE; Piecoro DW; McDonald RJ; Myint ZW; Hensley PJ; Allison DB
Hum Pathol; 2024 Jan; 143():42-49. PubMed ID: 38052269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
